Patents Assigned to Helmholtz Zentrum Muenchen Deutsches Forschungzentrum fuer Gesundheit und Umwelt GmbH
  • Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death
    Patent number: 10280179
    Abstract: The present invention relates to compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterized by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: May 7, 2019
    Assignee: HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH)
    Inventors: Marcus Conrad, Joel Schick, Bettina Proneth, Peter Sennhenn
  • Generation of antigen specific T cells
    Patent number: 8486694
    Abstract: The present invention is directed to a method of generating antigen specific T cells. Furthermore, the invention is directed to antigen specific T cells, isolated transgenic TCR's, pharmaceutical compositions containing same and their use in adoptive cell therapy. This invention in particular pertains to the use of cells co-expressing allogeneic MHC molecules and antigens to induce peptide-specific T cells from non-selected allogeneic T cell repertoires.
    Type: Grant
    Filed: August 4, 2006
    Date of Patent: July 16, 2013
    Assignees: Helmholtz Zentrum Muenchen Deutsches Forschungzentrum fuer Gesundheit und Umwelt GmbH, Max-Delbrueck-Centrum fuer Molekulare Medizin
    Inventors: Dolores Schendel, Susanne Wilde, Thomas Blankenstein